Current Hematologic Malignancy Reports

, Volume 6, Issue 2, pp 120–125 | Cite as

New Immunomodulatory Drugs in Myeloma

Article

Abstract

Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.

Keywords

Pomalidomide Lenalidomide Multiple myeloma Maintenance therapy Immunomodulatory drugs IMiDs 

Notes

Disclosure

Conflicts of interest: M. Lacy: Funds for clinical trials from Celgene.

References

Papers of particular interests, published recently, have been highlighted as:• Of importance

  1. 1.
    • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300. These are updated statistics regarding cancer incidence. PubMedCrossRefGoogle Scholar
  2. 2.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med. 1999;341:1565–71.PubMedCrossRefGoogle Scholar
  3. 3.
    • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. This study shows survival in myeloma by decade and suggests that novel therapies are having a positive impact on overall survival in myeloma. PubMedCrossRefGoogle Scholar
  4. 4.
    von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2008;81(4):247–52.CrossRefGoogle Scholar
  5. 5.
    Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.PubMedCrossRefGoogle Scholar
  8. 8.
    Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, Velcade and dexamethasone induces high response rates with comparable toxicity to Velcade alone and Velcade plus dexamethasone. Haematologica. 2007;92:1149–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138:330–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.PubMedCrossRefGoogle Scholar
  11. 11.
    Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–72.PubMedGoogle Scholar
  12. 12.
    Reece DE, Rodriguez GP, Chen C, et al. Phase I–II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26:4777–83.PubMedCrossRefGoogle Scholar
  13. 13.
    D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr AS. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30.PubMedCrossRefGoogle Scholar
  16. 16.
    • Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347–56. This shows the effects of IMiDs on p53. PubMedCrossRefGoogle Scholar
  17. 17.
    Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab. Br J Haematol. 2008;140:36–45.PubMedGoogle Scholar
  19. 19.
    Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380–6.PubMedGoogle Scholar
  20. 20.
    Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098–105.PubMedCrossRefGoogle Scholar
  22. 22.
    Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005;105:3833–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.PubMedCrossRefGoogle Scholar
  24. 24.
    D’Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001;28:597–601.PubMedCrossRefGoogle Scholar
  25. 25.
    Ferguson G, Jensen-Pergakes K, Wilkey C, et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007;27:210–20.PubMedCrossRefGoogle Scholar
  26. 26.
    • Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37. This trial established lenalidomide with low-dose dexamethasone as the standard for induction. PubMedCrossRefGoogle Scholar
  27. 27.
    • Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–86. This trial established the combination of lenalidomide, bortezomib, and dexamethasone. PubMedCrossRefGoogle Scholar
  28. 28.
    • Kumar SK, Flinn I, Noga SJ, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010;24:1350–6. This study established the four-drug combination of lenalidomide, bortezomib, cyclophosphamide, and dexamethasone. PubMedCrossRefGoogle Scholar
  29. 29.
    • McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]. ASH Annu Meet Abstr. 2010;116:37. This abstract reports on a CALGB trial of maintenance lenalidomide. Google Scholar
  30. 30.
    • Attal M, Lauwers VC, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract]. ASH Annu Meet Abstr. 2010;116:310. This abstract reports on the IFM trial of maintenance lenalidomide. Google Scholar
  31. 31.
    Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22:3269–76.PubMedCrossRefGoogle Scholar
  32. 32.
    Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141:41–51.PubMedCrossRefGoogle Scholar
  33. 33.
    • Richardson P, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib [abstract]. ASH Annu Meet Abstr. 2009;114:301. This abstract reports on a phase I trial of pomalidomide in heavily pretreated patients with refractory MM. Google Scholar
  34. 34.
    • Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27:5008–14. This article reports the first phase II trial of pomalidomide in relapsed MM. PubMedCrossRefGoogle Scholar
  35. 35.
    • Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934–9. This article reports the first phase II trial of pomalidomide in relapsed lenalidomide-refractory MM. PubMedCrossRefGoogle Scholar
  36. 36.
    • Kumar S, Blade J, Crowley J, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study [abstract]. ASH Annu Meet Abstr. 2009;114:2878. This abstract reports on prognosis in relapsed MM refractory to bortezomib and IMiD. Google Scholar
  37. 37.
    • Richardson PG, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib [abstract]. ASH Annu Meet Abstr. 2010;116:864. This abstract reports a phase II trial of pomalidomide in heavily pretreated patients with refractory MM. Google Scholar
  38. 38.
    • Leleu X, Attal M, Moreau P, et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02 [abstract]. ASH Annu Meet Abstr. 2010;116:859. This abstract reports a phase II trial of pomalidomide in heavily pretreated patients with refractory MM. Google Scholar
  39. 39.
    • Lacy M, Mandrekar S, Gertz MAA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease [abstract]. ASH Annu Meet Abstr. 2010;116:863. This abstract reports a phase II trial of pomalidomide in heavily pretreated patients with myeloma that is relapsing and refractory to both bortezomib and lenalidomide. Google Scholar
  40. 40.
    • Short KD, Rajkumar SV, Buadi F, et al. Increased incidence of extramedullary plasmacytomas in patients with multiple myeloma in the era of novel therapy and effect of pomalidomide on extramedullary disease [abstract]. ASH Annu Meet Abstr. 2010;116:3047. This is the first report of efficacy of pomalidomide in extramedullary disease. Google Scholar
  41. 41.
    • Geyer H, Viggiano R, Lacy M, et al. Acute lung toxicity related to pomalidomide. Chest. (in press). This is the first report of noninfectious pneumonitis due to pomalidomide. Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations